AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 287: E553-E557, 2004. First published May 18, 2004; doi:10.1152/ajpendo.00161.2004
0193-1849/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/3/E553    most recent
00161.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Khalili, L.
Right arrow Articles by Cartee, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Khalili, L.
Right arrow Articles by Cartee, G. D.

Prior serum- and AICAR-induced AMPK activation in primary human myocytes does not lead to subsequent increase in insulin-stimulated glucose uptake

Lubna Al-Khalili,1 Anna Krook,1 Juleen R. Zierath,1 and Gregory D. Cartee2

1Department of Surgical Science and Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden; and 2Department of Kinesiology, University of Wisconsin-Madison, Madison, Wisconsin 53706

Submitted 6 April 2004 ; accepted in final form 12 May 2004

Exposing isolated rat skeletal muscle to 5-aminoimidazole-4-carboxamide-1-{beta}-D-ribofuranoside [AICAR, a pharmacological activator of AMP-activated protein kinase (AMPK)] plus serum leads to a subsequent increase in insulin-stimulated glucose transport (Fisher JS, Gao J, Han DH, Holloszy JO, and Nolte LA. Am J Physiol Endocrinol Metab 282: E18–E23, 2002). Our goal was to determine whether preincubation of primary human skeletal muscle cells with human serum and AICAR (Serum+AICAR) would also induce a subsequent elevation in insulin-stimulated glucose uptake. Cells were preincubated for 1 h under 4 conditions: 1) without AICAR or serum (Control), 2) with serum, 3) with AICAR, or 4) with Serum+AICAR. Some cells were then collected for immunoblot analysis to assess phosphorylation of AMPK (pAMPK) and its substrate acetyl-CoA carboxylase (ACC). Other cells were incubated for an additional 4 h without AICAR or serum and then used to measure basal or insulin-stimulated 2-deoxyglucose (2-DG) uptake. Level of pAMPK was increased (P < 0.01) for myotubes exposed to Serum+AICAR vs. all other groups. Phosphorylated ACC (pACC) levels were higher for both Serum+AICAR (P < 0.05) and AICAR (P < 0.05) vs. Control and Serum groups. Basal (P < 0.05) and 1.2 nM insulin-stimulated (P < 0.005) 2-DG uptake was higher for Serum vs. all other preincubation conditions at equal insulin concentration. Regardless of insulin concentration (0, 1.2, or 18 nM), 2-DG was unaltered in cells preincubated with Serum+AICAR vs. Control cells. In contrast to results with isolated rat skeletal muscle, increasing the pAMPK and pACC in human myocytes via preincubation with Serum+AICAR was insufficient to lead to a subsequent enhancement in insulin-stimulated glucose uptake.

exercise; skeletal muscle; glucose transport; 5-aminoimidazole-4-carboxamide-1-{beta}-D-ribofuranoside; AMP-activated protein kinase



Address for reprint requests and other correspondence: G. D. Cartee, Kinesiology, Rm. 3040E, Univ. of Michigan, 401 Washtenaw Ave., Ann Arbor, MI 48109-2214 (E-mail: gcartee{at}umich.edu).




This article has been cited by other articles:


Home page
DiabetesHome page
N. Fujii, R. C. Ho, Y. Manabe, N. Jessen, T. Toyoda, W. L. Holland, S. A. Summers, M. F. Hirshman, and L. J. Goodyear
Ablation of AMP-Activated Protein Kinase {alpha}2 Activity Exacerbates Insulin Resistance Induced by High-Fat Feeding of Mice
Diabetes, November 1, 2008; 57(11): 2958 - 2966.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. Fujii, N. Jessen, and L. J. Goodyear
AMP-activated protein kinase and the regulation of glucose transport
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E867 - E877.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Christopher, C. Rantzau, Z.-P. Chen, R. Snow, B. Kemp, and F. P. Alford
Impact of in vivo fatty acid oxidation blockade on glucose turnover and muscle glucose metabolism during low-dose AICAR infusion
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1131 - E1140.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. C. Camacho, D. B. Lacy, F. D. James, E. P. Donahue, and D. H. Wasserman
5-Aminoimidazole-4-carboxamide-1-{beta}-D-ribofuranoside renders glucose output by the liver of the dog insensitive to a pharmacological increment in insulin
Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1039 - E1043.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
J. L. Smith, P. B. Patil, and J. S. Fisher
AICAR and hyperosmotic stress increase insulin-stimulated glucose transport
J Appl Physiol, September 1, 2005; 99(3): 877 - 883.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. R. Pencek, J. Shearer, R. C. Camacho, F. D. James, D. B. Lacy, P. T. Fueger, E. P. Donahue, W. Snead, and D. H. Wasserman
5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Causes Acute Hepatic Insulin Resistance In Vivo
Diabetes, February 1, 2005; 54(2): 355 - 360.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.